Amneal Q2 Net Revenue $796M, EPS $0.18; Raises 2026 Guidance
Amneal Pharmaceuticals reported strong second-quarter 2026 results with net revenue of $796 million, a 10% increase year-over-year, and GAAP net income of $58 million, up 157%. Diluted EPS reached $0.18, while adjusted diluted EPS was $0.30. The company also raised its full-year 2026 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS for the second time this year, reflecting confidence in its diversified portfolio and growth drivers. Additionally, a debt repricing in July is expected to reduce annual interest costs by $12 million.
Key Highlights
- Q2 2026 Net Revenue increased 10% to $796 million.
- Q2 2026 GAAP Net Income rose 157% to $58 million.
- Q2 2026 Diluted EPS was $0.18, up 157% year-over-year.
- Full-year 2026 Net Revenue guidance raised to $3.10B-$3.20B.
- Full-year 2026 Adjusted EBITDA guidance increased to $750M-$780M.
- Full-year 2026 Adjusted Diluted EPS guidance raised to $0.96-$1.06.
- Debt repricing in July 2026 to save $12 million annually in interest.
- Specialty net revenue grew 17%; Affordable Medicines net revenue grew 13%.
Price Impact
More from AMRX
Amneal Pharmaceuticals Acquires Kashiv BioSciences for $1.3B; Q3 Revenue $863M, Net Loss $(21.7)M
Amneal Pharmaceuticals Q3 Revenue $863M; Raises 2026 Guidance
Amneal Completes Kashiv BioSciences Acquisition for $375M Cash